
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. has demonstrated a strong launch trajectory for its commercial products, particularly Brinsupri, which is projected to achieve peak sales potential of over $9 billion in the near term, supported by positive feedback from healthcare professionals. The company has also reported consistent revenue growth for its product Arikayce, with a year-over-year increase of 19%, reinforcing its global expansion efforts and contributing to a total revenue guidance range of $450-$470 million for 2026. With the recent acceleration in Brinsupri sales, Insmed appears well-positioned to reach cash flow positivity without the need for additional capital, alleviating concerns regarding investor dilution.
Bears say
Insmed Inc has faced significant setbacks, notably the failure of brensocatib in the Phase 2b BiRCh study, which has caused a reduction in market expectations and the removal of CRSsNP sales from projections. Key concerns include potential deceleration in Brinsupri sales, a reset of out-of-pocket costs impacting prescription volumes, and the risk of missed endpoints in upcoming clinical trials, particularly in the ENCORE Phase 3 study and the CEDAR Phase 2b trial. Additionally, ongoing challenges in successfully executing clinical trials for Arikayce, brensocatib, and TPIP, coupled with high cash burn rates, could adversely impact Insmed’s overall financial stability and valuation.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares